In a study published in JAMA Network Open, SCoV-2 Ag Detect Rapid Self-Test demonstrated similar analytical and clinical performance across 3 phases of circulating SARS-CoV-2 variants (pre-Delta, Delta, and Omicron). Sequence analysis performed at InBios also suggests our test will detect variants currently in circulation. We routinely monitor sequences deposited in GISAID and Nextstrain for emerging SARS-CoV-2 mutations and variants and pay special attention to CDC data on circulating rates, and variants defined by the CDC as Variants of Concern (VoC) and Variants of Interest (VoI). Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time.